DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study

Ikuko Kato1,2, Kawsar Z Badsha3, Susan Land1,4, Jordan M Nechvatal,5 Larry H Matherly1,6, Adi L Tarca1,7, Adhip P Majumdar1,8, Marc D Basson1,9,10, and Jeffrey L Ram5

1Karmanos Cancer Institute, 2Department of Pathology, 3Department of Nutrition and Food Science, 4Department of Obstetrics and Gynecology, 5Department of Physiology, 6Department of Pharmacology, 7Department of Computer Science, 8Department of Internal Medicine, and 9Department of Surgery, Wayne State University, Detroit, MI; 10Surgical Service, John D Dingell VA Medical Center, Detroit, MI, USA

ABSTRACT

Aims and background. Exfoliated cells in human stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, and to evaluate the effects of exposures to exogenous and endogenous carcinogenic or chemopreventive substances. This pilot study investigated the feasibility of determining DNA methylation and RNA expression simultaneously in stool specimens treated with a single type of nucleic acid preservatives.

Methods. Stool specimens from 56 volunteers that were preserved up to a week with RNAlater were used in this study. Bisulfite sequencing was used to determine methylation at 27 CpG loci on the estrogen receptor 1 (ESR1) promoter. Taqman assay was used for quantitative reverse transcription polymerase chain reactions to measure cyclooxygenase 2 (COX2) and epidermal growth factor receptor (EGFR) mRNA expression. Subjects’ basic demographic and other selected risk factors for colorectal cancer were captured through questionnaires and correlated with the levels of these markers.

Results. Less than 10% of the samples failed in individual assays. Overall, 24.0% of the CpG loci on the ESR1 promoter were methylated. COX2 expression and alcohol use were positively correlated; an inverse association was present between EGFR expression and cigarette smoking; and subjects using anti-diabetic medication had higher ESR1 methylation. In addition, higher EGFR expression levels were marginally associated with history of polyps and family history of colorectal cancer.

Conclusions. The present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. Among several associations observed, the association between EGFR expression and polyps deserves further investigation as a potential target for colorectal cancer screening. Larger studies are warranted to confirm some of our observations.

Key words: stool test, DNA, RNA, colorectal cancer.

Acknowledgments: This research was supported by the Research Enhancement Program of Wayne State University. The authors thank Ms Ann Bankowski for study subject enrollment and for data and sample collection, and Ms Christina Haska for technical assistance in the development of methylation assays.

Correspondence to: Dr Ikuko Kato, Karmanos Cancer Institute, Wayne State University, 110 East Warren Avenue, Detroit, MI 48201 USA. Tel +1-313-5784206; fax +1-313-5784306; e-mail kato@karmanos.org

Received January 28, 2009; accepted May 14, 2009.